Reply to "Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky".
Development Department, Vaccine Division, The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN), Kita-ku Kumamoto-shi, Kumamoto, Japan yokote@kaketsuken.or.jp.
Hiroyuki
H
Yokote
Development Department, Vaccine Division, The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN), Kita-ku Kumamoto-shi, Kumamoto, Japan.
Yasuhiko
Y
Shinmura
D000818:Animals; D005260:Female; D016867:Immunocompromised Host; D012900:Smallpox Vaccine / Q000009:adverse effects*
D012900:Smallpox Vaccine